Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ARS-1 (Neffy) in Subjects with URTI
NCT04930900Phase 1Completed
- Sponsor
- ARS Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label trial of eurneffy in anaphylaxis (2 arms), sponsored by ARS Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve and 1 more. Started Aug 2021; status: completed.
02
Drugs
eurneffy
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT04930900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930900.